IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3Kδ inhibitor idelalisib

• Veronika Sandova,
• Gabriela Mladonicka Pavlasova,
• Vaclav Seda,
• Katerina Amruz Cerna,
• Sonali Sharma,
• Veronika Palusova,
• Yvona Brychtova,
• Sarka Pospisilova,
• Stacey M. Fernandes,
• Anna Panovska,
• Michael Doubek,
• Matthew S. Davids,
• Jennifer R. Brown,
• Jiri Mayer,
• Marek Mraz

Affiliations

Veronika Sandova

Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic

Gabriela Mladonicka Pavlasova

Central European Institute of Technology, Masaryk University, Brno, Czech Republic

Vaclav Seda

Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic

Katerina Amruz Cerna

Central European Institute of Technology, Masaryk University, Brno, Czech Republic

Sonali Sharma

Central European Institute of Technology, Masaryk University, Brno, Czech Republic

Veronika Palusova

Central European Institute of Technology, Masaryk University, Brno, Czech Republic

Yvona Brychtova

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic

Sarka Pospisilova

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic

Stacey M. Fernandes

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Anna Panovska

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic

Michael Doubek

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic

Matthew S. Davids

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Jennifer R. Brown

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Jiri Mayer

Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic

Marek Mraz

Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic